{"id":8480,"date":"2020-02-18T22:51:58","date_gmt":"2020-02-18T17:21:58","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=8480"},"modified":"2025-05-08T13:25:53","modified_gmt":"2025-05-08T07:55:53","slug":"car-tcr-summit","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/car-tcr-summit","title":{"rendered":"Why should every company working on CAR-T therapy attend CAR TCR Summit Europe?"},"content":{"rendered":"\n

The third edition of CAR-TCR Summit Europe<\/strong> is a one-stop platform that provides attendees with a holistic view of the Gene therapy market, listing the solutions to the plausible hurdles that come across in the process.
Hosting over 1000 industry-experts, the CAR TCR Summit is tailored for pharma & biotech players, cell therapy researchers, scholars, & clinicians, working directly in developing CAR-T therapies to find a cure for different types solid and liquid tumors and other Cell-storage and related logistics companies,  and industry service providers supplementing the advancement in the field. <\/p>\n\n\n\n

The four-day program digs deeper into the\nknow-hows of the CAR and TCR therapies and their scope in tackling several\ndebilitating and life-threatening diseases like Cancer. With two therapies, Kymriah<\/strong>,\nand Yescarta<\/strong> in the Oncology treatment market, and one – all set to\nenter the market – several other studies are ongoing in different geographies\nto target different types of cancers. <\/p>\n\n\n\n

However, the struggles the therapies have encountered to get the approval from the regulatory authority and then for the geographic expansion proved to be a significant barrier. The challenge did not just end there. The price tag attached posed a big question mark on their affordability, hence resulted in reluctant uptake in the hospitals. Despite the challenges that bumped into, the CAR -T therapy continues to advance, investments continue to soar, and the competition continues to unravel. <\/p>\n\n\n\n

Why attend CAR TCR Summit Europe? <\/h2>\n\n\n\n

The CAR TCR Summit proffers a convenient spot\nto address all the concerns of the attendees, with a promise to showcase the\nneed as well as the bright future of the CAR-T cell therapy in treating chronic\nconditions, presenting the innovations brought in the oncology therapy market\nby over 150 speakers, and strategizing the approaches that can help in tackling\nthe tailbacks of obstacles in producing, manufacturing, and commercializing the\ngene therapies. <\/p>\n\n\n\n

With the agenda to create a Cancer-free world<\/strong>, the essence of CAR TCR summit this year will revolve around technical bottlenecks that halt the therapy development at every stage of CAR-T drug development cycle across the three tracks, i.e., Translation<\/strong>, Manufacturing<\/strong>, and Development & Commercialization<\/strong>. <\/p>\n\n\n\n

Adorned with KOLs of several companies\nincluding CARsgen Therapeutics, Kite & Eureka Therapeutics, Gracell &\nTCBiopharm, and GammaDelta Therapeutics, Immatics & Gadeta, GlaxoSmithKline,\nBluebird Bio, and Celgene – developing CAR T therapies for different types of\ntumors at different stage of manufacturing – the summit offers an esteemed\nplatform to keep attendees abreast of parameters \u2013 technical, developmental, and\ncommercial. <\/p>\n\n\n\n

Gracell & TCBiopharm<\/strong> would help in identifying and expanding optimal T cell products, whereas CARsgen Therapeutics will share its views on overcoming tumour resistance for enhanced durability of response of the therapy. Similarly, Kite & Eureka Therapeutics<\/strong> will be sharing their experience in managing toxicity, and GammaDelta Therapeutics<\/strong> will be talking more about improving tumour targeting and safety profiles of allogeneic therapies. <\/p>\n\n\n\n

On a similar note, companies on Manufacturing track such as Immatics & Gadeta will be analyzing the technological advancements that have and may help in shorten down the process of manufacturing of CAR T therapy. Additionally, there would be discussions regarding CMC control, handling vector supply challenges by Alliance of Regenerative Medicine<\/strong> and GlaxoSmithKline<\/strong>, respectively. European regulatory authority EMA would also help in guiding Pharma and biotech players, and academia to carry out technology transfer efficiently. <\/p>\n\n\n\n

Moving towards the companies whose therapies had been or are on the cusp of commercialization, such as GlaxoSmithKline & Marker Therapeutics<\/strong> will be reminiscing about their journeys and the lessons learnt for better developmental decision making. MHRA & Celgene, on the other hand, would be helping and guidance through the regulatory process and initiation of clinical trials, specifically, in Europe.  Similarly, NICE<\/strong> &<\/strong> bluebird<\/strong> bio will be addressing early evidence criteria to achieve access and reimbursement with and NHS would be reviewing the operational challenges of running an effective CAR-T allogeneic trial. <\/p>\n\n\n\n

To summarize it, through garnering insights from various industry-experts the CAR TCR summit focuses in constructing an agenda to suit the needs of the attendees, guiding them through the process from pre-clinical till commercialization, and strategizing business decisions to identify potential partners. <\/p>\n","protected":false},"excerpt":{"rendered":"

The third edition of CAR-TCR Summit Europe is a one-stop platform that provides attendees with a holistic view of the Gene therapy market, listing the solutions to the plausible hurdles that come across in the process. Hosting over 1000 industry-experts, the CAR TCR Summit is tailored for pharma & biotech players, cell therapy researchers, scholars, […]<\/p>\n","protected":false},"author":1,"featured_media":8483,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[124,18055,810,1257,162,11389,18058,985,18056,18057,1693,18054,16932],"industry":[17225],"therapeutic_areas":[17235],"class_list":["post-8480","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-bluebird-bio","tag-car-tcr-summit-europe","tag-car-t","tag-car-t-therapy","tag-chimeric-antigen-receptor-car-t-cell-therapy","tag-conference","tag-gammadelta-therapeutics","tag-glaxosmithkline","tag-gracell-and-tcbiopharm","tag-kite-and-eureka-therapeutics","tag-kymriah","tag-oncology-treatment-market","tag-yescarta","industry-pharmaceutical","therapeutic_areas-cell-and-gene-therapy"],"acf":[],"yoast_head":"\nCAR TCR Summit Europe | Must-attend event for CAR-T therapy players<\/title>\n<meta name=\"description\" content=\"The CAR-TCR Summit Europe, a one-stop spot, helps in identifying hurdles and finding solutions that come in different stages of CAR-T therapy development.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/car-tcr-summit\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CAR TCR Summit Europe | Must-attend event for CAR-T therapy players\" \/>\n<meta property=\"og:description\" content=\"The CAR-TCR Summit Europe, a one-stop spot, helps in identifying hurdles and finding solutions that come in different stages of CAR-T therapy development.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/car-tcr-summit\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-02-18T17:21:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-08T07:55:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/02\/18180253\/Car-TCR-Summit-Europe-2020.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CAR TCR Summit Europe | Must-attend event for CAR-T therapy players","description":"The CAR-TCR Summit Europe, a one-stop spot, helps in identifying hurdles and finding solutions that come in different stages of CAR-T therapy development.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/car-tcr-summit","og_locale":"en_US","og_type":"article","og_title":"CAR TCR Summit Europe | Must-attend event for CAR-T therapy players","og_description":"The CAR-TCR Summit Europe, a one-stop spot, helps in identifying hurdles and finding solutions that come in different stages of CAR-T therapy development.","og_url":"https:\/\/www.delveinsight.com\/blog\/car-tcr-summit","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2020-02-18T17:21:58+00:00","article_modified_time":"2025-05-08T07:55:53+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/02\/18180253\/Car-TCR-Summit-Europe-2020.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/car-tcr-summit","url":"https:\/\/www.delveinsight.com\/blog\/car-tcr-summit","name":"CAR TCR Summit Europe | Must-attend event for CAR-T therapy players","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/car-tcr-summit#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/car-tcr-summit#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/02\/18180253\/Car-TCR-Summit-Europe-2020.jpg","datePublished":"2020-02-18T17:21:58+00:00","dateModified":"2025-05-08T07:55:53+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"The CAR-TCR Summit Europe, a one-stop spot, helps in identifying hurdles and finding solutions that come in different stages of CAR-T therapy development.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/car-tcr-summit"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/car-tcr-summit#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/02\/18180253\/Car-TCR-Summit-Europe-2020.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/02\/18180253\/Car-TCR-Summit-Europe-2020.jpg","width":772,"height":482,"caption":"Car-TCR Summit Europe 2020"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/02\/18180253\/Car-TCR-Summit-Europe-2020-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Bluebird bio<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">CAR TCR Summit Europe<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">CAR-T<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">CAR-T therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Chimeric Antigen Receptor (CAR) T-cell Therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Conference<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">GammaDelta Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">GlaxoSmithKline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Gracell And TCBiopharm<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Kite And Eureka Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Kymriah<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Oncology Treatment Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Yescarta<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Bluebird bio<\/span>","<span class=\"advgb-post-tax-term\">CAR TCR Summit Europe<\/span>","<span class=\"advgb-post-tax-term\">CAR-T<\/span>","<span class=\"advgb-post-tax-term\">CAR-T therapy<\/span>","<span class=\"advgb-post-tax-term\">Chimeric Antigen Receptor (CAR) T-cell Therapy<\/span>","<span class=\"advgb-post-tax-term\">Conference<\/span>","<span class=\"advgb-post-tax-term\">GammaDelta Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">GlaxoSmithKline<\/span>","<span class=\"advgb-post-tax-term\">Gracell And TCBiopharm<\/span>","<span class=\"advgb-post-tax-term\">Kite And Eureka Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">Kymriah<\/span>","<span class=\"advgb-post-tax-term\">Oncology Treatment Market<\/span>","<span class=\"advgb-post-tax-term\">Yescarta<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Feb 18, 2020","modified":"Updated on May 8, 2025"},"absolute_dates_time":{"created":"Posted on Feb 18, 2020 10:51 pm","modified":"Updated on May 8, 2025 1:25 pm"},"featured_img_caption":"Car-TCR Summit Europe 2020","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/8480","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=8480"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/8480\/revisions"}],"predecessor-version":[{"id":31966,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/8480\/revisions\/31966"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/8483"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=8480"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=8480"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=8480"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=8480"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=8480"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}